The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 ...
The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...
Marley was given Zolgensma, a life-changing gene therapy drug, at 16 months. According to SMA UK, the drug delivers a healthy copy of the affected gene to the body, but timing is critical because ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Topline results from a phase 3 clinical ...
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...
About SMA Spinal muscular atrophy (SMA) is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common ...
—The slow progression of SMA in adults and older children complicates evaluation of treatment response to newer therapies. Longitudinal quantitative MRI (qMRI) may give clinicians a better handle on ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results from the pivotal Part 2 of the FIREFISH ...
Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback